Anbogen Enters into Drug Supply Collaboration with BeiGene for Colorectal Cancer Therapy
Saturday, September 28, 2024
Anbogen has announced a drug supply collaboration with BeiGene to assess a combination treatment for metastatic colorectal cancer (mCRC).
Colorectal cancer is a major health issue, with over 1.9 million new cases reported worldwide in 2020.
This Phase II global trial will evaluate Anbogen’s HDAC inhibitor, ABT-301, alongside BeiGene’s anti-PD-1 antibody, tislelizumab, in patients with mismatch repair-proficient (pMMR) or microsatellite-stable (MSS) mCRC. BeiGene will provide tislelizumab for use in the study.
While immune checkpoint inhibitors (ICIs) have become a key treatment for mCRC with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), this approach benefits fewer than 5% of mCRC patients. The remaining 95% of patients, who have pMMR/MSS tumors, do not respond to ICIs, highlighting a significant unmet medical need.
ABT-301, an HDAC inhibitor, has already shown a favourable safety profile and pharmacokinetics in earlier trials. Preclinical data suggest that ABT-301 can improve the effectiveness of anti-PD-1 and anti-PD-L1 therapies by boosting CD8+ cytotoxic T cells and reducing monocytic myeloid-derived suppressor cells, which may help overcome resistance to ICIs in colorectal cancer.
The upcoming trial will explore the potential of ABT-301 combined with tislelizumab, both with and without bevacizumab, in treating pMMR/MSS mCRC patients.
The trial will be conducted at multiple sites, assessing the safety, tolerability, and early efficacy of these treatment regimens. Patient enrolment is expected to commence in the first quarter of 2025.
Source: anbogen.com
